/AMGEN%20Inc_%20logo%20on%20meds-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
Amgen is scheduled to report its first-quarter results next week, and analysts expect a single-digit earnings dip.
2 S&P 500 Stocks Worth Your Attention and 1 We Ignore
2 Dow Jones Stocks with Exciting Potential and 1 Facing Headwinds
Primary and Key Secondary Endpoints Met
- Collaboration with Amgen to explore the clinical potential of Zai Lab’s DLL3-targeting ADC, zocilurtatug pelitecan, in combination with Amgen’s IMDELLTRA ® ...
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention
2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds
/Biogen%20Inc%20logo%20on%20HQ-by%20Tada%20Images%20via%20Shutterstock.jpg)
Biogen has outperformed its sector peers recently, and analysts remain moderately optimistic about the stock’s prospects.
Q4 Earnings Highs And Lows: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks